Atara Biotherapeutics (ATRA) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free ATRA Stock Alerts $0.69 -0.02 (-3.30%) (As of 11:04 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAtara Biotherapeutics (NASDAQ:ATRA) Stock Price Crosses Below 50-Day Moving Average of $0.73americanbankingnews.com - April 18 at 4:12 AMAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - April 5 at 4:01 PMAnalysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)markets.businessinsider.com - April 1 at 3:20 PMATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 28 at 3:10 PMAtara Biotherapeutics: Q4 Earnings Insightsbenzinga.com - March 28 at 1:34 PMAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progressfinance.yahoo.com - March 28 at 1:34 PMAtara Biotherapeutics (NASDAQ:ATRA) Lowered to Sell at StockNews.commarketbeat.com - March 18 at 11:17 PMShort Interest in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Declines By 6.7%marketbeat.com - March 18 at 10:32 AMInsider Selling: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Sells 24,844 Shares of Stockinsidertrades.com - March 16 at 11:16 AMATRA Apr 2024 0.500 callfinance.yahoo.com - March 16 at 1:33 AMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Short Interest Up 44.4% in Februarymarketbeat.com - March 3 at 10:46 AMFDA clears Atara to begin Phase 1 study for lupus nephritis drugmsn.com - February 29 at 3:40 PMAtara Biotherapeutics Gets FDA Clearance for ATA3219 IND Applicationmarketwatch.com - February 29 at 10:40 AMAtara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapyfinance.yahoo.com - February 29 at 10:40 AMAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conferencefinance.yahoo.com - February 28 at 6:42 PMAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritisfinance.yahoo.com - February 14 at 1:46 PMAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritisbusinesswire.com - February 14 at 9:00 AMAtara Biotherapeutics Inc (ATRA)uk.investing.com - February 9 at 10:09 AMAtara Biotherapeutics, Inc. (0HIY.L)uk.finance.yahoo.com - February 6 at 1:38 PMAtara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runwayseekingalpha.com - February 5 at 8:16 PMAfter losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gainfinance.yahoo.com - February 3 at 12:52 PMSeth Klarman's Firm Exits Atara Biotherapeutics Inc Holdingfinance.yahoo.com - January 11 at 1:33 PMSeth Klarman's Exit from Atara Biotherapeutics Incfinance.yahoo.com - January 11 at 8:33 AMTab-cel BLA on Track for Submission in Q2 2024 Following Positive New Data from Pivotal ALLELE Studybusinesswire.com - January 9 at 7:21 AMAtara to conduct $15M registered direct offeringmsn.com - January 8 at 12:37 PMAtara Biotherapeutics Announces $15 Million Registered Direct Offeringfinance.yahoo.com - January 8 at 12:37 PMAtara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 8 at 8:25 AMAtara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 4 at 6:48 PMAtara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratoriesfinance.yahoo.com - December 20 at 6:38 PMAtara reportedly laying off 73 workers in wake of failed MS drug studymsn.com - December 19 at 1:37 PMNo Observed Treatment-Related Toxicities or Alloreactivitybusinesswire.com - December 11 at 10:17 PMAtara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meetingfinance.yahoo.com - December 11 at 12:15 PMAtara Biotherapeutics Inc ATRAmorningstar.com - December 8 at 11:51 PMAtara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023finance.yahoo.com - November 29 at 7:47 PMAtara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Whyfinance.yahoo.com - November 24 at 2:50 PMAtara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conferencefinance.yahoo.com - November 22 at 5:38 PMMizuho Downgrades Atara Biotherapeutics (ATRA)msn.com - November 10 at 9:25 AMHC Wainwright & Co. Downgrades Atara Biotherapeutics (ATRA)msn.com - November 10 at 4:25 AMWhy Atara Biotherapeutics Shares Are Plummeting Todaymsn.com - November 9 at 12:24 PMWhy Is Atara Biotherapeutics (ATRA) Stock Down 50% Today?investorplace.com - November 9 at 10:03 AMAtara stock plunges 50% after-hours on failed Phase 2 study for MS drugmsn.com - November 8 at 9:22 PMmarketbeat.com - November 8 at 5:30 PMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 5 at 3:04 PMPromising Outlook for Atara Biotherapeutics: Strategic Partnerships, Financial Stability, and Anticipated BLA Submissionmarkets.businessinsider.com - November 3 at 12:53 PMQ3 2023 Atara Biotherapeutics Inc Earnings Callfinance.yahoo.com - November 2 at 8:04 AMAtara Biotherapeutics Inc (ATRA) Announces Q3 2023 Financial Results and Expanded Global Partnershipfinance.yahoo.com - November 2 at 8:04 AMMizuho values Atara's US tab-cel deal at $450M, or $4/sharemsn.com - November 1 at 3:04 PMAtara licenses out US Tab-cel rights, plans to cut 30% of workforcemsn.com - November 1 at 1:16 PMAtara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 1 at 10:04 AMOptimistic Outlook for Atara Biotherapeutics: Unveiling of ATA188 Phase 2 Study and Anticipated Market Performancemarkets.businessinsider.com - October 9 at 3:47 PM Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street Legend Issues New NVDA Warning (Ad)Legendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock. Click here for the stock details ATRA Media Mentions By Week ATRA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRA News Sentiment▼0.590.44▲Average Medical News Sentiment ATRA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRA Articles This Week▼01▲ATRA Articles Average Week Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ATHA News CVM News PLX News ALVR News PASG News GRTS News CGTX News DTIL News CRIS News LGST News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATRA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
